Overview

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Status:
RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as first-line treatment in patients with KeAP1-mutated advanced or postoperative recurrent non-small cell lung cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Guangzhou Institute of Respiratory Disease